NCT06174935View on ClinicalTrials.gov

Low Dose Atropine for Symptomatic Vitreous Floaters

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2024

Conditions
Vitreous Floaters
Interventions
DRUG

0.01% atropine ophthalmic drop

0.01% atropine ophthalmic drop will be applied daily to the affected eye

Trial Locations (1)

20190

Retina Group of Washington, Reston

All Listed Sponsors
lead

Jeanette Du

OTHER